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The FFCD 9402 multicentre phase III trial was designed to compare the effects of
the combination of Transarterial Lipiodol Chemoembolisation (TACE) and tamoxifen
with tamoxifen alone on overall survival and quality of life in the palliative treatment
of hepatocellular carcinoma with cirrhosis. From 1995 to 2002, 138 patients were
randomised between the two groups. One hundred and twenty three patients were
eligible including 61 in the Tamoxifen group and 62 in the TACE group. Baseline
characteristics were similar: Child-Pugh class A: 70%, alcoholic cirrhosis: 76%,
Okuda stage I: 71%, multinodular tumour: 70% and segmental portal vein
thrombosis: 10%. At 2 years, the overall survival was 22% and 25% in the Tamoxifen
and TACE groups (P = .68), respectively. Multivariate analysis identified four
independent prognostic factors for survival: α-fetoprotein (AFP) > 400 ng/mL (P =
.008), abdominal pain (P = .011), hepatomegaly (P = .023) and Child-Pugh score (P
= .032). The Spitzer Index level assessing the quality of life during follow-up did not
differ between the two groups (P = .70). Amongst patients with stage Okuda I, the 2-
year overall survival was 28% in the Tamoxifen group and 32% in the TACE group (P
= .58). In this subgroup, two prognostic factors were statistically significant for
survival: AFP > 400 ng/mL (P = .004) and Spitzer Index (P = .013) as shown by
multivariable analysis.In conclusion, this study suggests that TACE improves neither
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